Antiangiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back

Antiangiogenesis and drug delivery to tumors: bench to bedside and back.

After over 30 years of preclinical and clinical development, antiangiogenic agents have recently entered the clinic as attractive targeted therapeutics for the treatment of cancer. Fueled by exciting new developments in the field, the AACR Special Conference was designed to broadly survey critical scientific advances in the antiangiogenic therapy of cancer. Because these advances have come prim...

Drug and gene delivery to the back of the eye: from bench to bedside.

Omar Consulting Group, LLC, Princeton Junction, New Jersey, United States University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States Pfizer, Inc., San Diego, California, United States University of Montreal, Montreal, Quebec, Canada DrugDel Consulting, LLC, Arlington, Texas, United States Emory University Eye Center, Atlanta, Georgia, United States University of Oklahoma He...

Coronary microembolization: from bedside to bench and back to bedside.

Coronary microembolization from the erosion or rupture of a vulnerable atherosclerotic plaque occurs spontaneously in acute coronary syndromes and iatrogenically during percutaneous coronary interventions. Typical consequences of coronary microembolization are microinfarcts with an inflammatory response, contractile dysfunction, and reduced coronary reserve. Apart from transient elevations of c...

From bedside to bench and back again.

Metabolic syndrome and cancer: from bedside to bench and back.

As older patients present with an average of three comorbidities beside their cancer, geriatric oncology can provide unique clues to translational research in aging and cancer. We illustrate this approach with the example of the metabolic syndrome and cancer. Epidemiologic and clinical cohorts highlighted an association between the metabolic syndrome and a higher risk and worse prognosis of var...